S-1/A: Encore Medical IPO to Fund PFO Device Clinical Trials

Encore Medical, a structural heart device company, is launching an IPO to raise approximately $12.7 million to finance U.S. clinical trials for its PFO septal occlusion device for stroke and migraine indications, aiming for a NYSE American listing.

Summary

• Encore Medical, Inc. is offering 3,000,000 shares of common stock at an expected initial public offering price of $5.00 per share, aiming to raise approximately $12.7 million in net proceeds.
• The primary purpose of the offering is to finance U.S. clinical trials for its PFO septal occlusion device for stroke ($7.2 million) and migraine ($2.0 million) indications, repay existing debt ($1.1 million secured, $650,000 short-term), and for working capital and general corporate purposes.
• The company specializes in transcatheter closure of cardiac defects, primarily Patent Foramen Ovale (PFO) and Atrial Septal Defects (ASD), with over 35,000 implants outside the U.S. to date.
• Encore Medical holds CE Mark approval for its products in the European Union and other countries (expiring December 31, 2027, renewal in process) but currently lacks U.S. FDA regulatory approval.
• An FDA Investigational Device Exemption (IDE) has been granted for the PFO stroke clinical trial, which is currently underway and estimated to take approximately two years to complete.
• For the fiscal year ended December 31, 2025, net sales increased by 21.1% to $2,585,858, with a gross profit of $1,037,556 (40.1% gross margin), but the company reported a net loss of $(928,088).
• As of December 31, 2025, the company had a cash balance of $94,256, an accumulated deficit of $(6,818,968), and a working capital deficit of $(1,766,486).
• The independent auditor has raised substantial doubt about the company's ability to continue as a going concern without additional capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative sentiment due to the company's significant historical losses and the auditor's going concern warning, which are partially offset by the substantial market potential of its PFO devices and the critical capital raise intended to address these issues and fund U.S. clinical trials.

Positives

• The company has over two decades of experience and 35,000+ global implantations of its core technology, providing a significant foundation of expertise and clinical confidence.
• Encore Medical's PFO closure device offers features such as ease of deployment, low metal mass, low profile, conformity to the septal wall, accessibility upon reintervention, and a low incidence of post-implant arrhythmia.
• The estimated annual market potential for PFO products for stroke prevention in the U.S. may exceed $1.5 billion, and the migraine market represents a multi-billion-dollar opportunity.
• The company has obtained CE Mark approval, enabling sales in the European Union and other international markets, and has successfully completed registrations in various non-EU jurisdictions.
• FDA Investigational Device Exemption (IDE) approval has been granted for the PFO septal occlusion device for stroke, and the clinical trial is underway with 13 patients enrolled and no reported complications or adverse events.
• Net sales increased by 21.1% from $2,134,528 in 2024 to $2,585,858 in 2025, driven by increased sales and marketing efforts, new markets, and a large fourth-quarter sale.
• Gross profit percentage improved to 40.1% in 2025 from 36.2% in 2024, partly due to improved productivity from a large sale.
• Net loss decreased from $(1,845,951) in 2024 to $(928,088) in 2025, indicating an improvement in financial performance.
• The company holds 9 granted and issued U.S. patents pertaining to its septal occlusion products and technologies, with two key patents having 15 and 5 years of useful life remaining.

Negatives

• The company has incurred net losses since inception, with a net loss of $(928,088) in 2025 and $(1,845,951) in 2024, and has an accumulated deficit of $(6,818,968) as of December 31, 2025.
• The independent registered public accounting firm has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows.
• The company currently does not have regulatory approval to sell its products in the United States, limiting its access to a significant market.
• New investors in the IPO will incur immediate and substantial dilution of $(3.87) per share, representing a significant difference between the offering price and the pro forma as adjusted net tangible book value.
• The company has significant customer concentration, with two customers accounting for 43.8% and 31.6% of total accounts receivable as of December 31, 2025, and four customers accounting for significant portions of 2025 sales.
• Dependence on Cardia, Inc. (a related party) for certain transitional commercial activities and collection of a $687,933 related-party receivable poses liquidity risks.
• The PFO closure procedure carries inherent risks such as stroke, infection, major bleeding, residual shunt, new-onset atrial fibrillation or flutter, frame fractures, perforations, device embolization, and thrombus formation.
• The device and procedure are unsuitable for patients with active infections, severe pulmonary or heart conditions, or allergies to nickel or other device materials.
• The company has significant indebtedness, including a $1,000,000 secured loan maturing in November 2026 and $350,000 in unsecured convertible promissory notes maturing in June 2026.
• The company does not intend to pay dividends on its common stock in the foreseeable future, meaning returns on investment will depend solely on stock price appreciation.

Risks

• Incurred net losses since inception and expect to incur net losses for the foreseeable future.
• Inability to receive approval for or complete clinical trials, or experiencing significant delays, could prevent or delay regulatory approval of the device and impair financial position.
• Clinical trial results may not be consistent with past experience and could hinder ability to succeed.
• The medical device industry is highly competitive and heavily regulated.
• New products or technological changes in the market could make it difficult to compete.
• Could face significant risk from product liability claims if products result in injury.
• Third-party reimbursement is essential to achieve the plan, and if limited or unavailable, it would have a material adverse impact on business and growth potential.
• Export and import regulations, including tariffs, could impact foreign operations.
• Regulatory reforms in the EU may make it more difficult and costly to market or distribute products.
• May be unable to enforce intellectual property rights.
• Will need additional capital to commercialize products and may be unable to continue as a going concern.
• May need to issue additional equity or take on debt financing that may be dilutive or detrimental to shareholders.
• Results could be adversely impacted by foreign currency fluctuations.
• All operations are conducted at one location, and any disruption at the facility could materially and adversely affect businesses.
• Dependent on vendors, consultants, Clinical Research Organizations (CROs), and other third parties.
• May need to implement a direct sales and marketing effort in the U.S., which could require significant additional capital without any assurance that the strategy will be successful.
• Dependent on a small number of employees to implement the plan and may be unable to retain or attract qualified personnel.
• Ownership is concentrated, and officers and directors have significant control.
• Conflicts of interest may arise from the dual roles occupied by the Chief Executive Officer, Vice President of Sales, and one director, and their ownership interests in the Company and Cardia, Inc.
• Shares may be thinly traded and have limited liquidity following the initial public offering.
• Investors will incur immediate and substantial dilution.
• Have not paid and do not intend to pay dividends.
• Investing in the offering is highly speculative and there is no assurance of a return on investment.
• Anti-takeover laws and provisions in governing documents may be detrimental to shareholders.
• May have to implement additional finance and accounting systems to operate as a public company and may be unable to file financial and other information on a timely basis.
• Business may be negatively impacted by natural disasters and future pandemics.
• Dependent on Cardia, Inc. for certain transitional commercial activities, and any failure by Cardia, Inc. to perform or remit amounts owed could adversely affect liquidity and results of operations.
• May experience difficulty enrolling patients in clinical trials, which could delay or prevent regulatory approval.
• Unfavorable outcomes from clinical trials could materially and adversely affect future products and business plans.
• Face pricing pressure from competitors, payors, and procurement practices, which may negatively impact margins.
• Failure to adequately maintain and protect personal information of customers or employees could have a material adverse effect on business.
• A failure of IT systems could have a material adverse impact on business operations and financial condition.
• Granted existing lender certain rights of first offer and other preferential rights, which could limit flexibility in future financing or strategic transactions.

Future Outlook

The company expects to incur net losses for the foreseeable future but anticipates that the net proceeds from this offering, combined with anticipated revenues, will be sufficient to fund operations for at least the next twelve months and complete the U.S. clinical trial for its stroke indication through full regulatory approval. However, additional capital may be required for later-stage migraine clinical trials. The company plans to renew its CE Mark approval by December 31, 2027, and intends to develop a direct U.S. sales and marketing team upon FDA approval. Management believes the public offering will alleviate its going concern issue and expects gross profit percentage to increase long-term as revenue grows, while selling, general, and administrative expenses are expected to increase in absolute terms due to public company costs and expansion, but decrease as a percentage of revenue.

Management Comments

• "We believe we have a superior closure device for treating PFO defects."
• "We are currently using cash flow from the sale of our products outside of the U.S. to help support our daily operations, and have commenced this offering primarily to finance our U.S. clinical trials for the stroke and migraine indications."
• "Management currently plans to seek additional equity financing; however, there is no assurance that this effort will be successful or sufficient to sustain operations beyond the next fiscal year."
• "Management monitors the receivable closely as part of its liquidity planning."
• "Management believes that the Company can successfully resolve its liquidity issues through these initiatives, there is significant uncertainty regarding the outcome."

Industry Context

StockSavvy.ai notes that Encore Medical operates in a highly competitive and regulated medical device industry, characterized by rapid technological change. Key competitors like Abbott Laboratories and W. L. Gore & Associates possess significantly greater resources and established market presence in the PFO device space. The company's strategy to enter the U.S. market hinges on successful FDA approvals, a common hurdle for emerging growth companies in this sector, while leveraging its existing CE Mark and international sales. The focus on PFO closure for stroke and migraine aligns with growing recognition of these indications, but market penetration will depend on clinical data, reimbursement, and physician adoption against entrenched players.

Comparison to Industry Standards

• Encore Medical's PFO device is positioned as having distinct advantages over competing first-generation devices from companies like Abbott and Occlutech, specifically citing its soft, conforming design, low metal content, and ease of future septal punctures.
• While Abbott and W.L. Gore & Associates currently hold FDA approval for PFO devices in the U.S., Encore Medical is still in the clinical trial phase for U.S. market entry, indicating it is behind these established players in the critical U.S. market.
• The estimated U.S. average retail price of approximately $11,000 for Encore's PFO products is substantially higher than its current international retail prices of $2,000 to $4,000, suggesting a significant revenue uplift potential upon successful U.S. commercialization.
• The company's 35,000+ global implantations outside the U.S. provide a strong clinical foundation, but this experience needs to be validated through successful U.S. clinical trials and regulatory approval to compete effectively with U.S. market leaders.
• The company's strategy to address both stroke and migraine indications for PFO closure aligns with evolving medical understanding and could open up a broader market compared to competitors focused solely on stroke prevention.

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceedings.

Related Party Transactions

• The company has a Contract Sales and Manufacturing Agreement (CSMA) with Cardia, Inc. (its former parent company), effective November 15, 2024, and amended December 12, 2025, which expires December 31, 2026.
• Under the CSMA, the company manufactures Cardia's Left Atrial Appendage product family and delivery system, and Cardia sells certain of the company's ASD products to fulfill existing supply contracts.
• As of December 31, 2025, there was a related-party receivable of $687,933 due from Cardia, Inc. for products shipped to the Ministry of Health of the Republic of Iraq.
• The company obtained an unsecured $250,000 line of credit with Cardia, Inc. on May 15, 2025 (amended October 1, 2025), with $216,000 drawn as of December 31, 2025.
• A $200,000 unsecured convertible promissory note was issued to CEO Joseph Marino on November 24, 2025, bearing 10% interest and maturing June 30, 2026.
• A $50,000 unsecured convertible promissory note was issued to board member Chris Turnbull on October 11, 2023 (amended November 24, 2025), bearing 10% interest and maturing June 30, 2026.
• Joseph A. Marino (CEO), Peter M. Buonomo (Senior Vice President), and Christopher Turnbull (Director) have overlapping roles and ownership interests in both Encore Medical, Inc. and Cardia, Inc.
• In 2024, the company recorded $475,538 of bad debt expense related to a Cardia receivable balance due to Cardia's limited revenue and future expectations.

Stakeholder Impact

• **Shareholders (Existing):** Will experience immediate and substantial dilution of their ownership interest due to the IPO. Their influence over matters submitted to shareholders for approval will remain significant due to concentrated ownership by officers and directors. No cash dividends are anticipated in the foreseeable future.
• **Shareholders (New IPO Investors):** Will incur immediate and substantial dilution. Investment involves a high degree of risk, and returns will depend solely on stock price appreciation, as no dividends are planned. The market price of common stock may be volatile and could decline below the IPO price.
• **Employees:** The anticipated growth and public company status will place increased demands on management and operational resources. The company is dependent on a small number of key employees, and competition for qualified personnel is intense.
• **Customers:** Existing international customers will continue to be served. Potential for new customers in the U.S. market if FDA approval is obtained for PFO devices. Risks related to product defects, safety issues, or recalls could impact customer confidence.
• **Suppliers/Vendors:** The company is dependent on certain vendors, consultants, and CROs for product development, manufacturing, testing, and regulatory clearance efforts. No long-term manufacturing arrangements exist, but multiple sources for raw materials are in place.
• **Creditors:** The IPO proceeds will be used to repay $1.1 million in secured debt and $650,000 in unsecured short-term debt, which should improve the company's debt profile and liquidity position, reducing immediate default risks.

Next Steps

• Complete the U.S. clinical trial for the PFO stroke indication (estimated two years to complete).
• Submit an FDA PMA application for final FDA approval of the PFO stroke device.
• Upon successful conclusion of the non-U.S. migraine study, apply for U.S. FDA IDE approval to conduct a U.S. clinical trial for the treatment of migraine headaches.
• Obtain renewal of the CE Mark under the European Medical Device Regulation (EU) 2017/745 prior to December 31, 2027.
• Develop and utilize a direct sales and marketing team in the United States once the PFO device is approved for sale.
• Actively pursue the transfer of regulatory approvals, licenses, and customer contracts to operate independently of the Contract Sales and Manufacturing Agreement (CSMA) with Cardia, Inc.
• Implement and improve operational systems, procedures, and controls to manage anticipated growth effectively.
• Implement additional finance and accounting systems, procedures, and controls to satisfy public company reporting requirements.
• File one or more registration statements on Form S-8 to register the offer and sale of shares under equity compensation plans.
• File one or more registration statements on Form S-1 for the resale of shares held by existing owners within six months following the closing of the offering.
• Joseph A. Marino will be replaced by Timothy G. Laske, PhD as a member of the governance committee within 12 months to meet independence requirements.
• Joseph A. Marino will be replaced by Timothy G. Laske, PhD as a compensation committee member within 12 months to ensure continued compliance with independence requirements.

Key Dates

Keywords

Medical Device, IPO, PFO, ASD, Structural Heart, Transcatheter, Stroke Prevention, Migraine Treatment, FDA Approval, CE Mark, Clinical Trials, Cardiovascular, Healthcare, Biotech, Minnesota